Organisation paid for research Program year 2025 Source: CMS Open Payments

Bruce Katz MD PC

Neither a doctor nor a teaching hospital

Research payments

$170,377

39 payments

Through program year 2025, Bruce Katz MD PC is reported as receiving $170,377 in research payments, across 39 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $3,254 2
2024 Research $3,064 5
2023 Research $7,877 5
2022 Research $30,226 9
2021 Research $104,099 7
2020 Research $11,656 8
2019 Research $10,200 3

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $114,525 7 payments
  2. AbbVie, Inc. $38,928 29 payments
  3. Bausch Health US, LLC $16,725 2 payments
  4. Endo Pharmaceuticals Inc. $200 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-To-Severe Atopic Dermatitis $57,770 2 payments
  2. Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis $36,624 1 payment
  3. M16-047 $21,656 10 payments
  4. A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Clinical Study to Compare the Safety and Efficacy of Idp-126 Gel to Epiduo? Forte Gel (0.3% Adapalene/2.5% Bpo), in the Treatment of Acne Vulgaris $16,725 2 payments
  5. A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $15,107 3 payments
  6. A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis $9,393 12 payments
  7. A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis $5,515 4 payments
  8. A Phase 3 16-Week Randomized Double-Blind Placebo-Controlled Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-To-Severe Atopic Dermatitis $5,024 1 payment
  9. A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (AD Up) $1,348 1 payment
  10. M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis $779 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record